Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852266 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase 1 study of Respiratory Syncytial Virus Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT01852266: Completed Phase 1 study of Respiratory Syncytial Virus Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01852266 is a Phase 1 study of Respiratory Syncytial Virus Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 50 participants, below the 1,089-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01852266, a Phase 1 study of Respiratory Syncytial Virus Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children. This study will evaluate the safety and immune response to an RSV vaccine in healthy RSV-naïve children.
Conditions Studied
Interventions
- BIOLOGICAL Placebo Vaccine
- BIOLOGICAL RSV cps2 Vaccine
Study Locations (2)
Maryland
- Johns Hopkins University, Center for Immunization Research (CIR) - Baltimore
- Johns Hopkins University, Center for Immunization Research South - Laurel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-10 |
| Phase | Phase 1 |
What the finished NCT01852266 record still lists
NCT01852266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,089-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo Vaccine is the first listed.
NCT01852266 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01852266 about?
NCT01852266 is a clinical study titled "Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children". Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children. This study will evaluate the safety and immune response to an RSV vaccine in healthy RSV-naïve children.
What is the current status of trial NCT01852266?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2013-10.
What conditions does trial NCT01852266 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT01852266?
The interventions under investigation include: Placebo Vaccine (BIOLOGICAL), RSV cps2 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01852266?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01852266 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01852266's enrollment target sits among peer trials
50 19th of 21 higher than 2 of 21 other Respiratory Syncytial Virus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of BLB-201 RSV Vaccine in Infants and Children
RECRUITING · Phase 1
-
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
COMPLETED · Phase 1
-
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
COMPLETED · Phase 1
-
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia